IMR Press / CEOG / Volume 46 / Issue 5 / DOI: 10.12891/ceog4876.2019

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Case Report
Effects of tadalafil on the uterine artery of fetal growth restriction
Show Less
1 Department of Obstetrics and Gynecology, Mie University Faculty Medicine, Mie, Japan
*Correspondence: (S. MAGAWA)
Clin. Exp. Obstet. Gynecol. 2019, 46(5), 833–835;
Published: 10 October 2019

Fetal growth restriction (FGR) is the most important cause of perinatal morbidity and mortality during the perinatal period. However, there is no established standard regarding the appropriate delivery time or treatment methods for fetuses with FGR. Reduced uterine arterial blood flow has been reported with FGR; however, if this is improved, then FGR may also be improved. Phosphodiesterase 5 inhibitors have vasodilating actions. When administered to the mother, they may improve FGR by improving fetal placental blood flow through improvements in uterine arterial blood flow.

Uterine artery bold flow
Fetal growth restriction
PDE5 inhibitor
Figure 1.
Back to top